Last reviewed · How we verify
Nuc-1031 and Carboplatin
Nuc-1031 and Carboplatin is a Small molecule drug developed by Imperial College Healthcare NHS Trust. It is currently in Phase 1 development.
At a glance
| Generic name | Nuc-1031 and Carboplatin |
|---|---|
| Sponsor | Imperial College Healthcare NHS Trust |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nuc-1031 and Carboplatin CI brief — competitive landscape report
- Nuc-1031 and Carboplatin updates RSS · CI watch RSS
- Imperial College Healthcare NHS Trust portfolio CI
Frequently asked questions about Nuc-1031 and Carboplatin
What is Nuc-1031 and Carboplatin?
Nuc-1031 and Carboplatin is a Small molecule drug developed by Imperial College Healthcare NHS Trust.
Who makes Nuc-1031 and Carboplatin?
Nuc-1031 and Carboplatin is developed by Imperial College Healthcare NHS Trust (see full Imperial College Healthcare NHS Trust pipeline at /company/imperial-college-healthcare-nhs-trust).
What development phase is Nuc-1031 and Carboplatin in?
Nuc-1031 and Carboplatin is in Phase 1.